Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominantly dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.
Clinical Trials Currently Ongoing
BN42358 PADOVA (Hoffmann-La Roche)
Victorine Sikati Foko Recruitment is closed
BIA 28-6156-201 ACTIVATE (Bial R&D Investments)
Victorine Sikati Foko Recruitment is closed
Completed Clinical Trials
2023 BIAL (Phase II)
2021: BN42358 study (Phase IIb)
2014: iSTEP study (Phase III)
2011: CONFIDENT-PD study (Phase II)
2010: AFQ056A2217 study (Phase II)
2010: AFQ056A2208 study (Phase II)
Symptoms & Cause
Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. People with PD may experience:
Tremor, mainly at rest and described as pill-rolling tremor in hands. Other forms of tremor are possible
Bradykinesia
Limb rigidity
Gait and balance problems
The cause remains largely unknown. Although there is no cure, treatment options vary and include medications and surgery. While Parkinson’s itself is not fatal, disease complications can be serious.
Diagnose & Treatment
There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s — particularly in its early stages — is difficult.
There is no standard treatment for Parkinson’s disease (PD). Treatment for each person with Parkinson’s is based on his or her symptoms. Treatments can include medications, physical therapy, surgical options, medical marijuana, clinical trials, lifestyle modifications, like getting more rest and exercise.
There are many medications available to treat Parkinson’s symptoms, although none yet that reverse the effects of the disease. It is common for people with PD to take a variety of these medications — all at different doses and at different times of day — to manage symptoms.
Importance of clinical research
Scientists and doctors are working together to find a treatment or prevention technique.
The clinical research will help to attract the attention of the federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing PD. This is an important first step to better understanding who develops PD and why.
We participate in a number of clinical trials aiming to create advancements for the treatment of Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective.
Cutting edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and, most importantly, to help advance the treatments themselves.
When it comes to Neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of Doctors, Nurses and, most of all, patients.
Maladie de Parkinson
La maladie de Parkinson (MP) est un trouble neurodégénératif complexe et progressif qui touche à la fois les systèmes nerveux central et périphérique. Elle se caractérise par l’accumulation d’une protéine appelée alpha-synucléine dans les cellules cérébrales et par la perte graduelle de neurones producteurs de dopamine, essentiels au contrôle fluide des mouvements.
La MP peut se manifester par un ensemble de symptômes, notamment :
Tremblement
Rigidité
Ralentissement des mouvements et de la pensée
Perte d’équilibre
Instabilité de la pression artérielle
Troubles neuropsychiatriques
À la CNO, nous adoptons une approche multidisciplinaire pour le diagnostic et la prise en charge de la maladie de Parkinson, en offrant un continuum de soins qui inclut des thérapies standards et émergentes.
Nos services comprennent :
Un diagnostic clinique spécialisé par des neurologues experts des troubles du mouvement
À propos de la SMTr pour la maladie de Parkinson :
La SMTr est une technique non invasive qui utilise des impulsions magnétiques ciblées pour moduler l’activité cérébrale. Les études (voir les publications) suggèrent qu’elle pourrait aider à atténuer certains symptômes, tels que :
Le ralentissement moteur
Blocage soudain à l'initiation de la marche
Les troubles cognitifs
Bien que prometteuse, la SMTr demeure un traitement expérimental pour la maladie de Parkinson et n’est pas actuellement couverte par les régimes publics d’assurance maladie (RAMQ/OHIP).